Sapio Sciences announces immediate availability of Exemplar LIMS/ELN 9.0
Sapio Sciences LLC has announced the release of Exemplar LIMS/ELN 9.0. With this Exemplar LIMS software release Sapio has significantly expanded the scalability of both the LIMS and ELN to support huge amounts of data without impacting general system performance. Many other key features have been added to extend Sapio’s technological and usability leadership position including a responsive interface and color coded fields.
Sapio introduced the initial Exemplar ELN with its 8.0 Exemplar release in 2016. Important enhancements have been added to Exemplar ELN to enable more powerful template creation supporting ELN experimental workflows. Complex experiment templates can now easily be created with Exemplar ELN without requiring consulting. Exemplar 9.0 also introduces scripting support so the Exemplar platform on both the LIMS and ELN fronts can have rules added using popular languages like Python and JavaScript in addition to our long-supported Java plugins.
According to Kevin Cramer, chief executive officer, “Pharma and Biotech companies are challenged to find best in class LIMS and ELN solutions to support their research and clinical operations. Typically, this meant buying two distinct solutions and then either resigning to the fact that they are not integrated, or undertaking a costly and cumbersome integration process. With Exemplar LIMS/ELN 9.0 there is no need to compromise anymore. You can get a best in class LIMS and ELN in one, fully integrated solution out of the box. This can lead to significant savings in time and money for large enterprises versus buying point solutions.”
Kevin continues, “We have already garnered significant LIMS plus ELN wins in 2017 and we look forward to this trend continuing for the rest of the year. Sapio is very customer driven, so as uptake of Exemplar ELN accelerates we will continue to listen closely to our customer’s feedback on how best to improve Exemplar’s capabilities and ease of use in support of their R&D objectives.”